Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2016-000373-21
    Sponsor's Protocol Code Number:IRX-22015A
    National Competent Authority:Hungary - National Institute of Pharmacy
    Clinical Trial Type:EEA CTA
    Trial Status:Prematurely Ended
    Date on which this record was first entered in the EudraCT database:2017-06-26
    Trial results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedHungary - National Institute of Pharmacy
    A.2EudraCT number2016-000373-21
    A.3Full title of the trial
    A Randomized Phase 2 Trial of Neoadjuvant and Adjuvant Therapy with the IRX-2 Regimen in Patients with Newly Diagnosed Stage II, III or IVA Squamous Cell Carcinoma of the Oral Cavity
    Az IRX‑2 kezeléssel végzett neoadjuváns és adjuváns terápia randomizált, fázis II. vizsgálata újonnan diagnosztizált, II., III. vagy IVA stádiumú szájüregi laphámsejtes carcinomában szenvedő betegeknél
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    A Randomized Phase-2 Trial to Evaluate the Effects of the IRX-2 Regimen before Surgery and after Chemotherapy or Radiation in Newly Diagnosed Patients with Stage II, III or IVA Squamous Cell Cancer of the Oral Cavity
    Az IRX-2 kezelés randomizált, fázis II hatásértékelő vizsgálata műtét előtt és kemoterápia vagy surgárkezelés után, újonnan diagnosztizált, II., III. vagy IVA stádiumú szájüregi laphámsejtes carcinomában szenvedő betegeknél.
    A.4.1Sponsor's protocol code numberIRX-22015A
    A.5.2US NCT (ClinicalTrials.gov registry) numberNCT02609386
    A.7Trial is part of a Paediatric Investigation Plan No
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorIRX Therapeutics, Inc.
    B.1.3.4CountryUnited States
    B.3.1 and B.3.2Status of the sponsorCommercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportIRX Therapeutics, Inc.
    B.4.2CountryUnited States
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationIRX Therapeutics, Inc.
    B.5.2Functional name of contact pointSteven Younger
    B.5.3 Address:
    B.5.3.1Street Address140-A 58th Street, Suite 2100
    B.5.3.2Town/ cityBrooklyn, New York
    B.5.3.3Post code11220
    B.5.3.4CountryUnited States
    B.5.4Telephone number+1917703-0655
    B.5.5Fax number+1212582-3659
    B.5.6E-mailsyounger@irxtherapeutics.com
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameIRX-2
    D.3.4Pharmaceutical form Solution for injection
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPSubcutaneous use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNINN not yet proposed see D.3.9.3
    D.3.9.2Current sponsor codeIRX-2
    D.3.9.3Other descriptive name Primary Cytokine Components: IL-2, IL-1β, IFN-γ and TNF-α.
    D.3.10 Strength
    D.3.10.1Concentration unit Other
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number115
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin No
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) Yes
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) Yes
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 2
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameCyclophosphamide
    D.3.4Pharmaceutical form Powder for solution for injection/infusion
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPIntravenous use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNCYCLOPHOSPHAMIDE
    D.3.9.1CAS number 50-18-0
    D.3.9.4EV Substance CodeSUB06859MIG
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typerange
    D.3.10.3Concentration number500 to 1000
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 3
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameIndometacin
    D.3.4Pharmaceutical form Capsule
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNIndometacin
    D.3.9.3Other descriptive nameINDOMETACIN
    D.3.9.4EV Substance CodeSUB08180MIG
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number25
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 4
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameOmeprazole
    D.3.4Pharmaceutical form Capsule
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNOmeprazole
    D.3.9.3Other descriptive nameOMEPRAZOLE
    D.3.9.4EV Substance CodeSUB09439MIG
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number20
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 5
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.1.1.1Trade name Forceval
    D.2.1.1.2Name of the Marketing Authorisation holderAlliance Pharmaceuticals Ltd.
    D.2.1.2Country which granted the Marketing AuthorisationUnited Kingdom
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameZinc-containing multivitamins
    D.3.4Pharmaceutical form Capsule
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNzinc sulphate
    D.3.9.1CAS number 7733-02-0
    D.3.9.4EV Substance CodeSUB12619MIG
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typerange
    D.3.10.3Concentration number15 to 30
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNMultivitamins and minerals
    D.3.9.3Other descriptive nameMultivitamins and minerals
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 6
    D.1.2 and D.1.3IMP RoleComparator
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameCyclophosphamide
    D.3.4Pharmaceutical form Powder for solution for injection/infusion
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPIntravenous use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNCYCLOPHOSPHAMIDE
    D.3.9.1CAS number 50-18-0
    D.3.9.4EV Substance CodeSUB06859MIG
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typerange
    D.3.10.3Concentration number500 to 1000
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 7
    D.1.2 and D.1.3IMP RoleComparator
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameIndometacin
    D.3.4Pharmaceutical form Capsule
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNIndometacin
    D.3.9.3Other descriptive nameINDOMETACIN
    D.3.9.4EV Substance CodeSUB08180MIG
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number25
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 8
    D.1.2 and D.1.3IMP RoleComparator
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameOmeprazole
    D.3.4Pharmaceutical form Capsule
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNOmeprazole
    D.3.9.3Other descriptive nameOMEPRAZOLE
    D.3.9.4EV Substance CodeSUB09439MIG
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number20
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 9
    D.1.2 and D.1.3IMP RoleComparator
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.1.1.1Trade name Forceval
    D.2.1.1.2Name of the Marketing Authorisation holderAlliance Pharmaceuticals Ltd.
    D.2.1.2Country which granted the Marketing AuthorisationUnited Kingdom
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameZinc-containing multivitamins
    D.3.4Pharmaceutical form Capsule
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNzinc sulpahate
    D.3.9.1CAS number 7733-02-0
    D.3.9.3Other descriptive nameZINC
    D.3.9.4EV Substance CodeSUB12619MIG
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typerange
    D.3.10.3Concentration number15 to 30
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNMultivitamins and minerals
    D.3.9.3Other descriptive nameMultivitamins
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    Newly Diagnosed Stage II, III or IVA Squamous Cell Carcinoma of the Oral Cavity.
    Újonnan diagnosztizált II., III. vagy IVA stádiumú szájüregi laphámsejtes carcinoma
    E.1.1.1Medical condition in easily understood language
    You have recently been found to have advanced cancer in your oral cavity, called squamous cell cancer of the oral cavity.
    Nemrég Önnél előrehaladott -a szájüregében kialakult- rákot állapítottak meg, úgynevezett laphámsejtes szájüregi karcinómát.
    E.1.1.2Therapeutic area Diseases [C] - Cancer [C04]
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 20.0
    E.1.2Level PT
    E.1.2Classification code 10041857
    E.1.2Term Squamous cell carcinoma of the oral cavity
    E.1.2System Organ Class 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
    E.1.3Condition being studied is a rare disease No
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    The primary objective is to determine if the event-free survival (EFS) of subjects treated with Regimen 1 (IRX-2 Regimen with cyclophosphamide, indomethacin, zinc, omeprazole and IRX-2)
    is longer than for subjects treated with Regimen 2 (Regimen 1 with cyclophosphamide, indomethacin, zinc, omeprazole but without IRX-2).
    Exploratory objectives for the detection of biological activity, prognostic and predictive factors, and clinical-pathologic-immunologic correlates, are included and defined in the protocol. The key exploratory endpoints will be analysed separately from, and not affect the primary endpoint analysis.
    Az elsődleges célkitűzés annak meghatározása, hogy az 1. kezelésben (IRX‑2 kezelés ciklofoszfamiddal, indometacinnal, cinkkel, omeprazollal és IRX-2-vel) részesült vizsgálati alanyoknál hosszabb‑e az eseménymentes túlélés (event‑free survival, EFS), mint azoknál a vizsgálati alanyoknál, akik a 2. kezelést (1. kezelés ciklofoszfamiddal, indometacinnal, cinkkel, omeprazollal, de IRX‑2 nélkül) kapták.
    A protokoll magában foglalja és meghatározza a feltáró jellegű végpontokat a biológiai aktivitás, a kutatási és előrejelzési faktorok és klinikai-szövettani-immunológiai összefüggések tekintetében.
    E.2.2Secondary objectives of the trial
    Secondary objectives are:
    1. to determine if OS of subjects treated with Regimen 1 is longer than for subjects treated with Regimen 2;
    2. to compare the safety of each Regimen;
    3. to compare the feasibility of each Booster Regimen.
    Másodlagos célkitűzések:
    1) annak meghatározása, hogy az 1. kezelésben részesült vizsgálati alanyoknál hosszabb‑e a teljes túlélés (overall survival, OS), mint azoknál a vizsgálati alanyoknál, akik a 2. kezelést kapták.
    2)az egyes kezelések biztonságosságának összehasonlítása.
    3)az egyes hatásfokozó kezelések kivitelezhetőségének összehasonlítása.
    E.2.3Trial contains a sub-study No
    E.3Principal inclusion criteria
    1. Pathologically confirmed diagnosis of Stage II, III or IVA squamous cell cancer of the oral cavity (excluding the lip). Staging must be done using AJCC Cancer Staging Manual Edition 7.0.
    2. Subjects: males or females at least 18 years of age at study entry.
    3. Disease is surgically resectable with a curative intent.
    4. Karnofsky Performance Status ≥ 70%.
    5. Haematological, Hepatic and Renal functions are adequate for surgical intervention.
    6. Females of child-bearing potential must have negative urine/serum pregnancy test and agree to used a highly effective form of birth control.
    7. Subjects are able to give Informed Consent and adhere to the protocol treatment plan.
    1. Kórszövettani vizsgálattal igazolt, II, III vagy IVA klinikai stádiumú szájüregi laphámsejtes carcinoma (az ajak kivételével). A stádium meghatározásának az "AJCC Cancer Staging Manual" 7.0 kiadása szerint kell történnie.
    2. Alanyok: A vizsgálatba való belépéskor legalább 18 éves férfiak vagy nők
    3. Kuratív célú műtéti reszekcióra alkalmas betegség
    4. Karnofsky‑féle teljesítmény státusz (KPS) ≥70%
    5. Sebészeti beavatkozásra alkalmas hematológiai-, máj- és vesefunkciók
    6. Negatív terhességi teszt vizeletből vagy vérből megállapítva, és hajlanóság nagy hatékonyságú fogamzásgátló módszer alkalmazására a fogamzóképes nőknél.
    7. Beleegyező nyilatkozat tételére, valamint a protokoll kezelési tervét betartani képes alanyok.
    E.4Principal exclusion criteria
    1. Prior surgery, radiation or chemotherapy (excluding biopsy or any procedure required for supportive care).
    2. Tumour of the oropharynx.
    3. Tumour involvement likely to be associated with T4b cancer.
    4. Distant metastased (M1 disease).
    5. Diagnosis of another invasive cancer which is currently not in remission and has required treatment within the last 5 years.
    6. Known infection with hepatitis B, C or HIV.
    7. Use of any Investigational agent within 30 days of randomization.
    8. Symptomatic cardiopulmonary disease which are not clinical stable.
    9. Myocardial infarction within the last 3 months.
    10. Stroke or other cerebral vascular insufficiency within last 3 months.
    11. Daily use systemic immunosuppressive therapy or corticosteroids (except for hormone deficiency) 30 days prior to randomization.
    12. Known allergies to ciprofloxacin(or other quinolones) acetylsalicylic acid or indomethacin.
    1.Korábbi műtét, sugárterápia, kemoterápia (kivéve a biopsziát vagy a szupportív ellátáshoz szükséges bármely beavatkozást.)
    2.Oropharyngealis tumor.
    3.T4b stádiumú carcinomára utaló tumor érintettsége
    4.Távoli áttét (M1 stádiumú betegség).
    5. Egyéb diagnosztizált invazív carcinoma, melynek tekintetében az egyén nem tekinthető betegségmentesnek, és amely az elmúlt 5 évben kezelést igényelt.
    6.Ismert hepatitis B‑, hepatitis C‑ vagy HIV‑fertőzés.
    7.Bármilyen vizsgálati készítmény alkalmazása a rendomizációt megelőző 30 napon belül.
    8.Tünetekkel járó cardiopulmonalis betegség amely klinikailag nem stabil.
    9.Myocardialis infarctus az elmúlt 3 hónapban.
    10.Stroke vagy cerebrovascularis insufficientia az elmúlt 3 hónapon belül.
    11.Szisztémás immunszuppresszív terápia vagy kortikoszteroidok napi alkalmazása a randomizációt megelőző 30 napban (kivéve hormonhiány kezelésére).
    12. Ciprofloxacinnal (vagy egyéb kinolonokkal), acetilszalicilsavval vagy indometacinnal szembeni allergia.
    E.5 End points
    E.5.1Primary end point(s)
    The primary endpoint is event-free survival (EFS).
    Progression prior to surgical resection will not be considered an Event, but failure to resect tumor that was apparent at randomization for any reason or the presence of gross residual disease at surgery will be considered an Event. Progression after resection should be confirmed by biopsy, but in the absence of biopsy confirmation, unequivocal clinical evidence of progression in the primary or nodal sites or distant metastatic disease using RECIST v1.1 criteria will be accepted as progression. Scans (CT, MRI or PET) should be performed to restage disease and establish patterns of relapse. The date of progression will be the date on which the decision not to resect tumor that was apparent at randomization is made or the date upon which the Investigator first observes recurrent locoregional or metastatic disease by physical or radiologic examination. Death for any cause will also be considered an Event. Diagnosis of a second malignancy will not be considered an Event, but date of diagnosis, site and histology will be collected.
    Elsődleges célkitűzés az eseménymentes túlélés (event‑free survival, EFS). A műtéti reszekciót megelőző progresszió nem minősül eseménynek, ugyanakkor a randomizáció időpontjában látott tumor bármilyen okból sikertelen reszekcióját eseménynek tekintik. A reszekció utáni progressziót biopsziával kell igazolni. Biopszia eredmény hiányában a nyirokcsomó vagy távoli metasztázis nem egyértelmű progressziójának megállapítására a RECIST v1.1 kritériumok elfogadottak progresszióként. Valamint ismételt stádiummeghatározást („re‑staging”) kell végezni képalkotó vizsgálatokkal (CT, MRI vagy PET), és meg kell határozni a relapszus jellemzőit. A progresszió dátuma az a nap lesz, amelyen a randomizációkor látott tumor reszekciójának mellőzésére vonatkozó döntést meghozták, vagy amelyen a vizsgáló első alkalommal állapítja meg locoregionalis vagy metastaticus betegség kiújulását fizikális vagy radiológiai vizsgálattal. A bármilyen okból bekövetkező elhalálozás szintén eseménynek számít. Második rosszindulatú daganat diagnózisát nem tekintik eseménynek, de a diagnózis dátumát, helyét és szövettani típusát regisztrálják.
    E.5.1.1Timepoint(s) of evaluation of this end point
    EFS will be assessed by physical examination at routine follow-up visits every 3 months after surgery for the first two years and every 6 months during years 3 and 4 and by chest CT scans performed yearly x 4 years.
    Az EFS‑t fizikális vizsgálattal fogják meghatározni a műtét utáni első két évben 3 havonta, majd a 3. és 4. évben 6 havonta rutinszerűen végzett utánkövetési viziteken, valamint a 4 éven át évente végzett mellkas CT‑vizsgálatokkal
    E.5.2Secondary end point(s)
    The secondary endpoints are overall survival (OS) and safety and feasibility.
    Survival data will be collected in all subjects (phone contact after progression will be sufficient). When the subject comes to clinic and/or is contacted by phone, the date of that contact is to be reported as an update of the subject’s survival.
    Safety of each Regimen and feasibility of the Booster Regimens will be assessed by the incidence and severity of AEs, SAEs, and subject discontinuations.
    Másodlagos végpontok a teljes túlélés (overall survival OS), biztonságosság és megfelelőség.
    Valamennyi vizsgálati alany esetében gyűjtik a túlélésre vonatkozó adatokat (a progresszió után telefonos kapcsolattartás elegendő). Az egyes kezelések biztonságosságát, valamint a hatásfokozó kezelések kivitelezhetőségét a nemkívánatos események előfordulási gyakorisága és intenzitása, súlyos nemkívánatos események előfordulása, valamint a vizsgálati részvétel abbahagyása alapján értékelik.
    E.5.2.1Timepoint(s) of evaluation of this end point
    Survival data will be collected at each study visit after surgery at 3, 6, 9, 12, 15, 18, 21, 24, 30, 36, 42, and 48 months with telephone calls for survival status to occur every 3 months if subject is not seen in follow-up until data collection ceases.
    All subjects will be assessed for AEs as detailed in the study schedule. AEs will be measured from day of randomisation until 30 days post-surgery and subsequently from the first day of each booster Regimen until 30 days after the completion. SAEs will be measured from day of randomization until the subject ends the trial.
    A túlélési adatok a műtét utáni 3, 6, 9, 12, 15, 18, 21, 24, 30, 36, 42, és 48 vizsgálati viziteken kerülnek összegyűjtésre telefonos utánkövetés útján, azért, hogy 3 havonata követve legyen a betegek túlélése, amíg az adatgyűjtés befelyeződik.
    Minden betegnél nemkívánatos esemény értékelés történik a vizsgálati tervben leírtak szerint.
    A nemkívánatos események mérése a randomizáció napjától kezdődően, a műtétet követő 30 napig tart, valamint ezt követően az egyes hatásnövelő kezelések első napjától a befejezés utáni 30 napig.
    A súlyom nemkívánatos események mérése a randomizáció napjától a beteg vizsgálatának befelyezéséig tart.
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy Yes
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic No
    E.6.7Pharmacodynamic No
    E.6.8Bioequivalence No
    E.6.9Dose response No
    E.6.10Pharmacogenetic No
    E.6.11Pharmacogenomic Yes
    E.6.12Pharmacoeconomic No
    E.6.13Others Yes
    E.6.13.1Other scope of the trial description
    Exploratory objectives:
    - changes in tumor size from baseline to surgery;
    - lymphocyte infiltrates in the pre-treatment tumor biopsy, the surgical specimen and changes between these two samples.
    Additional exploratory objectives:
    - surgical pathology;
    - prognostic and predictive factors and clinical-pathologic-immunologic correlates;
    - Human papilloma virus (HPV) status;
    - the peripheral T cell receptor profile;
    - RNA expression profiling of immune-inflammatory markers.
    Feltáró jellegű végpontok:
    - A tumor méretében bekövetkezett változás az alapállapottól a műtéti állapotig.
    - lymphocytás infiltráció a műtét előtti biopsziás mintákban, a műtéti mintákban és a változás a két minta között
    További feltáró jellegű végpontok:
    - műtéti pathológia
    - kutatási és előrejelzési faktorok és klinikai-szövettani-immunológiai összefüggések
    - Humán papilloma vírus (HPV) státusz
    - perifériás T sejt receptor profil
    - RNA expresszió profil és gyulladási markerek.
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E.7.1.3.1Other trial type description
    E.7.2Therapeutic exploratory (Phase II) Yes
    E.7.3Therapeutic confirmatory (Phase III) No
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled Yes
    E.8.1.1Randomised Yes
    E.8.1.2Open Yes
    E.8.1.3Single blind No
    E.8.1.4Double blind No
    E.8.1.5Parallel group Yes
    E.8.1.6Cross over No
    E.8.1.7Other No
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) No
    E.8.2.2Placebo No
    E.8.2.3Other Yes
    E.8.2.3.1Comparator description
    The comparator treatment regimen, has the same components except for IRX-2.
    E.8.2.4Number of treatment arms in the trial2
    E.8.3 The trial involves single site in the Member State concerned No
    E.8.4 The trial involves multiple sites in the Member State concerned Yes
    E.8.4.1Number of sites anticipated in Member State concerned3
    E.8.5The trial involves multiple Member States Yes
    E.8.5.1Number of sites anticipated in the EEA19
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA Yes
    E.8.6.2Trial being conducted completely outside of the EEA No
    E.8.6.3If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned
    Brazil
    Canada
    Germany
    Hungary
    Italy
    Serbia
    Spain
    Switzerland
    United Kingdom
    United States
    E.8.7Trial has a data monitoring committee Yes
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    LVLS
    Az utolsó beteg utolsó vizite (LVLS)
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years5
    E.8.9.1In the Member State concerned months0
    E.8.9.1In the Member State concerned days0
    E.8.9.2In all countries concerned by the trial years6
    E.8.9.2In all countries concerned by the trial months6
    E.8.9.2In all countries concerned by the trial days0
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 No
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.5Children (2-11years) No
    F.1.1.6Adolescents (12-17 years) No
    F.1.2Adults (18-64 years) Yes
    F.1.2.1Number of subjects for this age range: 100
    F.1.3Elderly (>=65 years) Yes
    F.1.3.1Number of subjects for this age range: 100
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations Yes
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception Yes
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally No
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state24
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 96
    F.4.2.2In the whole clinical trial 200
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    There are no plans for treatment or care after the subject has ended his/her participation in the trial other than standard of care.
    A beteg vizsgálati részvételének befejezését követően nincs tervezett kezelés vagy gondozás a bevett ellátáson felül.
    G. Investigator Networks to be involved in the Trial
    G.4 Investigator Network to be involved in the Trial: 1
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2017-09-05
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2017-08-22
    P. End of Trial
    P.End of Trial StatusPrematurely Ended
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 02 05:26:09 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA